je.st
news
Tag: squibb
Vetr Inc. Lowers Bristol-Myers Squibb Co (BMY) to Hold
2016-04-05 10:56:15| Biotech - Topix.net
They presently have a $67.61 target price on the biopharmaceutical company's stock. Vetr 's target price suggests a potential upside of 2.49% from the company's current price.
Bristol-Myers Squibb To Acquire Padlock Therapeutics, Inc.
2016-03-30 03:53:43| drugdiscoveryonline Home Page
Bristol-Myers Squibb Company and Padlock Therapeutics, Inc. announced recently that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases
Tags: acquire
therapeutics
squibb
padlock
BTR Capital Management Has $520,000 Position in Bristol-Myers Squibb Co
2016-02-10 07:01:40| Biotech - Topix.net
BTR Capital Management raised its position in shares of Bristol-Myers Squibb Co by 8.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,565 shares of the biopharmaceutical company's stock after buying an additional 600 shares during the period.
Tags: management
position
capital
squibb
Oncodesign Biotechnology And Bristol-Myers Squibb Enter Into Strategic Drug Discovery Collaboration
2016-01-06 06:00:34| drugdiscoveryonline Home Page
ONCODESIGN (Alternext – ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, recently announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds
Tags: enter
drug
collaboration
strategic
GSK to buy HIV drugs from Bristol-Myers Squibb for initial $350 million
2015-12-18 11:02:16| Biotech - Topix.net
It used to dominate the market but ViiV's 2014 sales of 1.5 billion pounds were less than a quarter of the HIV revenue generated by market leader Gilead Sciences ViiV will pay an initial $317 million to buy late-stage HIV drug candidates from Bristol-Myers, including a phase III development treatment fostemsavir, plus $33 million for its preclinical assets. HIV is often treated by mixing at least three medicines together because of the ability of the virus that causes AIDS to mutate and become drug-resistant.
Tags: buy
million
initial
drugs